Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
CMND · NASDAQ · Pharmaceutical Preparations · Foreign private issuer
Clearmind Medicine (CMND) · oqro.io/stocks/CMND · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$4.53−0.09 (−1.95%)
Close of Nov 13, 2026, vs Nov 12 · end-of-day, not a live quote
No open-market purchase by an insider of Clearmind Medicine was filed in the last 90 days. The latest on record was on Jun 12, 2026.
Since 2026, Clearmind Medicine insiders reported 1 open-market purchase and 4 sales on Forms 4 and 5, with purchases in 1 different year, most recently 2026.
No open-market sale by an insider of Clearmind Medicine (CMND) was filed with the SEC in the last 90 days.
No trade in Clearmind Medicine (CMND) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−99.6% (−$1,103.31) from Nov 13, 2025 to Nov 13, 2026 · adjusted daily closes
Adjusted close went from $1,107.84 on Nov 13, 2025 to $4.53 on Nov 13, 2026 (−99.6%). Disclosed in this range: 5 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Vancouver, British Columbia, Canada (Federal Level). Foreign private issuer: reports on Form 20-F or 40-F.
Pharmaceutical Preparations company based in Vancouver, British Columbia, Canada (Federal Level). Foreign private issuer: reports on Form 20-F or 40-F. Its directors and officers file insider-trading forms (Form 4) only since 18 March 2026.
Last 12 months
−99.6%
Market value
–
S&P 500 +12.3% over the same dates. Prices adjusted for splits and dividends.
Short interest: 1,160 shares sold short, −70.0% vs the previous count, 1.0 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Traded Jun 12 – Jun 16, 2026 · largest single transaction ~$73KNot reported under a pre-arranged trading plan
Jun 16, 2026~$73K · 22K sh @ $3.31
Jun 15, 2026~$11K · 3,183 sh @ $3.32
DetailsOfficial recordJun 12, 2026~$7.1K · 2,102 sh @ $3.36
DetailsOfficial recordInsider buying
Traded Jun 10 · filed 2 days later
Since the trade −82.3% · S&P 500 +4.0% · to Nov 13
A major shareholder of Clearmind Medicine paid $330K out of pocket for Clearmind Medicine shares.
Insider selling
Traded Jun 11 · filed 1 day laterNot reported under a pre-arranged trading plan
Since the trade −83.0% · S&P 500 +2.3% · to Nov 13
A major shareholder of Clearmind Medicine sold $28K of Clearmind Medicine shares. The filing does not indicate a pre-arranged trading plan.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Insiders of Clearmind Medicine reported 1 open-market purchase and 4 sales since 2026; purchases in 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $330K1×1 trade | $119K4×4 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
0 active phase 3 trials and 1 active phase 2 trial led by this company, mostly in alcohol use disorder. The ones with the nearest registered primary completion date still ahead:
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
Against the S&P 500 over the year
Since Nov 12, 2025, CMND is down 99.5% and the index fund is up 10.4%: 110 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much CMND moves
End-of-day prices. These figures describe the past year and say nothing about what comes next.
On the public record for Clearmind Medicine over the 12 months to Nov 15, 2026: 1 clinical trial.
